129,960 Shares in Cardiff Oncology, Inc. (NASDAQ:CRDF) Acquired by Boothbay Fund Management LLC

Boothbay Fund Management LLC bought a new stake in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund bought 129,960 shares of the company's stock, valued at approximately $564,000. Boothbay Fund Management LLC owned 0.25% of Cardiff Oncology at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in CRDF. Raymond James Financial Inc. acquired a new position in shares of Cardiff Oncology during the 4th quarter worth approximately $56,000. Voya Investment Management LLC acquired a new stake in Cardiff Oncology during the 4th quarter worth approximately $57,000. Mariner LLC purchased a new position in Cardiff Oncology in the fourth quarter valued at $61,000. Intech Investment Management LLC purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at about $79,000. Finally, Thoroughbred Financial Services LLC grew its holdings in Cardiff Oncology by 43.8% during the 4th quarter. Thoroughbred Financial Services LLC now owns 19,614 shares of the company's stock worth $85,000 after acquiring an additional 5,970 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Stock Down 4.2 %

Shares of CRDF traded down $0.11 during mid-day trading on Tuesday, reaching $2.57. 174,816 shares of the stock traded hands, compared to its average volume of 1,118,283. The stock has a fifty day simple moving average of $3.25 and a 200 day simple moving average of $3.48. Cardiff Oncology, Inc. has a 12-month low of $2.01 and a 12-month high of $5.64. The firm has a market cap of $170.77 million, a price-to-earnings ratio of -2.69 and a beta of 1.81.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright boosted their target price on Cardiff Oncology from $13.00 to $17.00 and gave the company a "buy" rating in a report on Friday, February 28th.

Cardiff Oncology Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.